Tiludronic acid

Drug Profile

Tiludronic acid

Alternative Names: Cl-TMBP; ME 3737; Skelid; SR 41319; SR 41319B; Tiludronate; Tiludronate sodium

Latest Information Update: 17 Mar 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer Meiji Seika Kaisha; Meiji Seika Pharma; Sanofi; Sanofi Winthrop
  • Class Antihypercalcaemics; Bisphosphonates; Calcium regulators; Osteoporosis therapies
  • Mechanism of Action Bone resorption factor inhibitors; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Osteitis deformans
  • Discontinued Postmenopausal osteoporosis; Rheumatoid arthritis

Most Recent Events

  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 27 Aug 1999 Sanofi and Synthélabo have merged to form Sanofi-Synthélabo
  • 12 Jun 1998 Launched for Osteitis deformans in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top